Venetoclax with azacitidine (ven/aza) has emerged as a promising treatment regimen for
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia
stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated …

We previously demonstrated that leukemia stem cells (LSCs) in de novo acute myeloid
leukemia (AML) patients are selectively reliant on amino acid metabolism and that treatment …

Background BCL‐2 inhibition through venetoclax (VEN) targets acute myeloid leukemia
(AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield …

Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …

Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML).
Here we define a 'MitoScore'signature, which identifies high mitochondrial oxidative …

Simple Summary Venetoclax has proven to be a promising therapy for newly diagnosed,
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …

Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …

Despite the success of the combination of venetoclax with the hypomethylating agents
(HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients …

Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been
the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this …